These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 22613854)

  • 21. Drug eruptions: approaching the diagnosis of drug-induced skin diseases.
    Nigen S; Knowles SR; Shear NH
    J Drugs Dermatol; 2003 Jun; 2(3):278-99. PubMed ID: 12848112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review.
    Moustou AE; Matekovits A; Dessinioti C; Antoniou C; Sfikakis PP; Stratigos AJ
    J Am Acad Dermatol; 2009 Sep; 61(3):486-504. PubMed ID: 19628303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psoriasiform eruption induced by infliximab.
    Verea MM; Del Pozo J; Yebra-Pimentel MT; Porta A; Fonseca E
    Ann Pharmacother; 2004 Jan; 38(1):54-7. PubMed ID: 14742794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lichenoid tissue reaction/interface dermatitis: recognition, classification, etiology, and clinicopathological overtones.
    Sehgal VN; Srivastava G; Sharma S; Sehgal S; Verma P
    Indian J Dermatol Venereol Leprol; 2011; 77(4):418-29; quiz 430. PubMed ID: 21727689
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New drug therapies and their effect on the skin.
    Treudler R
    J Dtsch Dermatol Ges; 2009 Jul; 7(7):623-37. PubMed ID: 19614812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Adverse cutaneous reactions to drugs in neurology].
    Redondo Bellón P
    Rev Neurol; 1997 Sep; 25 Suppl 3():S309-19. PubMed ID: 9273176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice.
    Surguladze D; Deevi D; Claros N; Corcoran E; Wang S; Plym MJ; Wu Y; Doody J; Mauro DJ; Witte L; Busam KJ; Pytowski B; Rodeck U; Tonra JR
    Cancer Res; 2009 Jul; 69(14):5643-7. PubMed ID: 19584274
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allergic cutaneous reactions to drugs.
    Bigby M; Stern RS; Arndt KA
    Prim Care; 1989 Sep; 16(3):713-27. PubMed ID: 2529577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cutaneous side effects of gold therapy. Clinical and histologic results].
    Hofmann C; Burg G; Jung C
    Z Rheumatol; 1986; 45(3):100-6. PubMed ID: 2944308
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Side-effects of beta-receptor blockaders on the skin].
    Hödl S
    Z Hautkr; 1983 Jan; 58(1):17-28. PubMed ID: 6131557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review.
    Grinblat B; Scheinberg M
    Semin Arthritis Rheum; 2008 Feb; 37(4):251-5. PubMed ID: 17640718
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histopathological and immunohistochemical features of drug-induced exanthems.
    Lisi P; Pelliccia S; Bellini V
    G Ital Dermatol Venereol; 2014 Apr; 149(2):237-41. PubMed ID: 24819645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions.
    de Gannes GC; Ghoreishi M; Pope J; Russell A; Bell D; Adams S; Shojania K; Martinka M; Dutz JP
    Arch Dermatol; 2007 Feb; 143(2):223-31. PubMed ID: 17310002
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The usefulness of skin tests to prove drug hypersensitivity.
    Lammintausta K; Kortekangas-Savolainen O
    Br J Dermatol; 2005 May; 152(5):968-74. PubMed ID: 15888154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Lichenoid eruptions after gold therapy. Report of two cases].
    Lasarowa AZ; Tsankov NK; Stoimenov AP
    Hautarzt; 1992 Aug; 43(8):514-6. PubMed ID: 1387122
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The immune system of the skin and stereotyped reaction patterns in inflammatory skin diseases].
    Jaspars EH
    Ned Tijdschr Geneeskd; 2006 Apr; 150(17):948-55. PubMed ID: 17225734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cutaneous reactions to practolol. Clinical and histopathological study.
    Kauppinen K; Niemi KM; Salo OP
    Ann Clin Res; 1976 Aug; 8(4):232-40. PubMed ID: 136919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cutaneous reactions to epidermal growth factor receptor inhibitors.
    Pomerantz RG; Mirvish ED; Geskin LJ
    J Drugs Dermatol; 2010 Oct; 9(10):1229-34. PubMed ID: 20941947
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Defining urticarial dermatitis: a subset of dermal hypersensitivity reaction pattern.
    Kossard S; Hamann I; Wilkinson B
    Arch Dermatol; 2006 Jan; 142(1):29-34. PubMed ID: 16415383
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histopathological Spectrum and Immunophenotypic Characterization of Symmetrical Drug-Related Intertriginous and Flexural Exanthema.
    Muresan AM; Metze D; Böer-Auer A; Braun SA
    Am J Dermatopathol; 2021 Feb; 43(2):103-111. PubMed ID: 32618703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.